Coenzyme Q10
Aliases: CoQ10 · Ubiquinol/Ubiquinone
Last verified: 2026-09-23
The short version
A mitochondrial lipid cofactor — electron transporter in the ETC; proven benefit in heart failure (Q-SYMBIO) and statin myalgia.
Identity & type
- Molecular type
- mali molekul
- Origin
- A mitochondrial lipid cofactor — electron transporter in the ETC; proven benefit in heart failure (Q-SYMBIO) and statin myalgia.
Mechanism of action
ETC shuttle + membrane antioxidant.
Dosing & routes
Official / clinical context
Approved drug — indications, dosing and warnings are defined by the official label. 100–300 mg/day (ubiquinol better absorbed).
Regulator-approved labeling and published study designs — never a recommendation.
Community-reported practice
100–300 mg/day (ubiquinol better absorbed). Statin users report less muscle pain; in CHF — better function. Anti-aging effects are subtle.
Unverified self-reports. Not medical advice. Not endorsement.
Expected effects (community)
Statin users report less muscle pain; in CHF — better function. Anti-aging effects are subtle.
Protocol — official vs community
Official / label
Supplement; statin-mitochondrial rationale. Studies used 100–300 mg daily (ubiquinone or ubiquinol).
- 01100 mg daily with a fatty meal
Duration: Continuous.
Fat-soluble — the 'with food' instruction is pharmacology, not etiquette.
Community (anecdotal)
100–200 mg daily with the largest meal; ubiquinol form preferred by older users.
- Cycle:
- Continuous.
- Break:
- None.
Statin users are the evidence-anchored population; longevity use is extrapolation downward in risk.
Human evidence
Q-SYMBIO RCT: −43% cardiac mortality in CHF.
Preclinical evidence
The preclinical phase was completed and submitted to regulators as part of registration; pharmacology and toxicology details are part of the official label.
Known risks
- Rare GI upset.characterized
Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.
Unknowns & evidence gaps
- Real-world data outside controlled trials